Business Context and Reporting Period
Company: CURIS, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2001
Business Overview: Curis focuses on regenerative medicine, utilizing functional genomics and developmental biology to activate cellular pathways for tissue repair and inhibit abnormal growth for cancer treatment. The company was formed via a July 2000 merger of Creative BioMolecules, Ontogeny, and Reprogenesis.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2001 |
Six Months Ended June 30, 2001 |
|---|---|---|
| Revenues | $202,638 | $451,803 |
| Net Loss | $(19,277,008) | $(37,084,237) |
| Net Loss Per Share (Basic/Diluted) | $(0.61) | $(1.18) |
| Operating Cash Flow | N/A | $(11,722,968) |
| Cash and Cash Equivalents | $42,426,951 | $42,426,951 |
| Total Debt (Current + Long-Term) | $7,639,536 | $7,639,536 |
| Intangible Assets (Net) | $85,498,343 | $85,498,343 |
Material Changes vs. Prior Period
- Revenue: Three-month revenue increased significantly to $202,638 from $7,471 in the prior year, driven by National Institute of Standards and Technology (NIST) grants. However, six-month revenue decreased 33% to $451,803 from $677,858, primarily due to the absence of a $661,000 license revenue from Stryker recognized in the prior year.
- Expenses: Operating expenses surged due to the consolidation of the 2000 merger.
- R&D Expenses: Increased 313% (3-month) and 302% (6-month) year-over-year.
- Amortization: Amortization of intangible assets (goodwill and assembled workforce) rose to $5.8 million (3-month) and $11.6 million (6-month) compared to negligible amounts in 2000.
- Stock-Based Compensation: Increased to $3.7 million (3-month) and $7.5 million (6-month) due to amortization of prepaid compensation from the merger and new option grants.
- Net Loss: Net loss widened substantially to $19.3 million (3-month) and $37.1 million (6-month) compared to $2.5 million and $8.4 million in the prior year periods.
Outlook, Risks, and Unusual Items
- Liquidity: As of June 30, 2001, the company held approximately $59 million in cash, cash equivalents, and marketable securities. Management anticipates these resources, combined with proceeds from Micromet and Elan transactions, will fund operations into the second quarter of 2003.
- Recent Transactions:
- Micromet AG: Assigned single-chain polypeptide technology for $8 million cash, stock, and a convertible note. Revenue recognition is deferred over the performance period.
- Elan International Services: Formed a joint venture ("Newco") for hedgehog signaling pathway research. Curis invested $12 million in preferred stock and received an $8 million convertible note from Elan Pharma International Limited.
- Accounting Changes: Adoption of SFAS No. 142 (effective Jan 1, 2002) will cease goodwill amortization, reducing annual operating expenses by approximately $11.5 million, though goodwill will be subject to annual impairment testing.
- Risks: Future funding depends on regulatory approvals for Stryker products (OP-1), successful collaborations, and additional equity/debt financing. Failure to secure funding or approvals could materially adversely affect the business.
Investor Verification Checklist
- Runway: Verify if the projected cash runway into Q2 2003 remains valid given the high burn rate ($37M loss in 6 months).
- Revenue Recognition: Confirm the timeline for recognizing the $8 million Micromet transaction and the $12 million deferred revenue from the Elan collaboration.
- Goodwill Impairment: Monitor the impact of SFAS 142 adoption in 2002; while amortization stops, a one-time impairment charge could occur if fair value tests fail.
- Debt Covenants: Review terms of the $2 million Becton Dickinson note and the $8 million Elan note regarding conversion triggers and interest rates.
- Regulatory Status: Track the approval status of the OP-1 product with Stryker, as royalty revenue is contingent on commercial sale.